() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Category Archives: PreveCeutical Medical

PreveCeutical Announces Launch of Cannabis Division

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in keeping with the Company's vision of becoming a global preventive healthcare company, PreveCeutical has launched a medicinal cannabis division (the "Cannabis Division").
Read more

PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that, further to its news release dated August 8, 2017, it has entered into a research and option agreement (the “Research Agreement”), with the University of Queensland (“UQ”) and UniQuest Pty Limited (“UniQuest”), UQ’s main commercialisation company. Pursuant to the Research Agreement, the parties intend to conduct a research program (the “Research Program”) which expands the use of their disulfide linker technology and seeks to develop non-addictive analgesics for the treatment of pain, which may offer an alternative to addictive opioids. The opioid epidemic has led to significant numbers of opioid-related deaths and addictions, taxing public health care systems and affecting social and economic welfare.
Read more
Get $50 in free trades.